Related by context. Frequent words. (Click for all words.) 74 Initiates Phase II 73 FDA Accepts 72 Receives Orphan Drug Designation 72 Presents Positive 71 Completes Enrollment 69 Commences Phase 69 Initiate Phase 68 Pivotal Phase III 68 Drug Candidate 67 Pivotal Study 67 Transcept Pharmaceuticals 67 Phase III Clinical Trial 67 Patient Enrollment 67 FDA Clears 66 Initiates Phase 66 Announces FDA Clearance 66 Clinical Trial Results 66 Pivotal Trial 65 Receives FDA Clearance 65 Generic Version 65 gets USFDA nod 64 Develop Novel 64 submitted Biologics License 64 Preclinical Data 64 Announces Initiation 64 Panzem R 64 Pivotal Phase 64 Single Dose 64 Receives Positive 63 Phase III Trial 63 FDA Approves 63 Inc Therapeutic Competitors 63 Files Shelf Registration Statement 63 Extended Release 63 Extended Release Tablets 63 Cholesterol Drug 63 Recombinant Human 62 Receives Patent 62 Small Molecule 62 Application MAA 62 Reports Positive 62 Updates Status 62 Shows Promise 62 Announces Positive 62 CRTX 62 FDA Complete Response 62 Announces Stockholder Approval 62 Kuvan R 62 Release Tablets 62 Receives Notice 62 Telavancin 61 Issues Guidance 61 Fibrocell Science Inc. 61 IND Investigational New 61 Complete Response 61 Patent Covering 61 Inc. NASDAQ QLTI 61 Receives Regulatory 61 RNAi Therapeutics 61 Drug Submission 61 SBIR Grant 61 Significantly Reduces 61 Low Dose 61 BioGlue R 61 Seeks Approval 61 Announces Presentation 61 Q3 Loss Widens 60 Announces Dismissal 60 application sNDA 60 submitted Marketing Authorization 60 refractory chronic lymphocytic 60 FDA Clearance 60 FDA Orphan Drug 60 Wins Approval 60 II Clinical Trial 60 Act PDUFA date 60 Reduces Risk 60 Q4 Loss Widens 60 Q2 Loss Narrows 60 R sorafenib tablets 60 LGND 60 Announces Successful Completion 60 Daclizumab 60 Improves Survival 60 Inc. Nasdaq IMGN 60 Announces Filing 60 Gets Approval 60 Announces Shareholder Approval 60 Announces Termination 60 NASDAQ SHPGY 60 Study Demonstrates 60 DRRX 59 Announces Issuance 59 Investigational Device Exemption 59 Metastatic Melanoma 59 Positive Opinion 59 Q2 Loss Widens 59 Application BLA 59 BPAX 59 Ambrisentan 59 Receives CE